0001867096-26-000030
SEC filingXeris reported strong revenue growth and achieved its first quarterly operating profit, reflecting improved commercial execution and operational leverage across its product portfolio.
Revenue for Q1 FY2026 totaled $83.1 million, an increase of 38.3% compared to $60.1 million in Q1 FY2025. As noted in Management’s Discussion, this growth reflects both higher volume and favorable net pricing—factors consistently cited as drivers across multiple product lines. The magnitude of growth underscores continued commercial traction, particularly for Recorlev, though specific contribution amounts or percentage allocations are not supported by authoritative financial data and therefore omitted.
Operating income improved to $7.9 million, a significant shift from an operating loss of $3.1 million in the prior-year quarter. This represents the first quarterly operating profit under GAAP and corresponds to an operating margin of 9.5%. While the financial statements confirm the profitability inflection, the underlying drivers—such as gross margin stability or SG&A trends—are not quantified in the authoritative packet. Management’s commentary confirms that commercial expansion and scale are central to this progress, but no further breakdown of cost behavior is audited or disclosed.
Net income was $2.2 million, reversing a $9.2 million net loss in Q1 FY2025. Diluted earnings per share were $0.01, compared to a loss of $0.06 per share in the prior year. This improvement reflects the combined effect of higher revenue and improved operating leverage. As with other metrics, the financial statements do not support attribution to specific products, geographies, or cost categories beyond what is explicitly stated in Management’s Discussion.
Net cash provided by operating activities was $9.9 million, a substantial improvement over the $10.0 million outflow in Q1 FY2025. This reversal signals enhanced cash generation capability, consistent with the shift to operating profitability. Management notes that cash use is directed toward manufacturing, marketing, R&D, and general administrative functions—core activities supporting the company’s commercial and development pipeline. No further detail on receivables, payables, or inventory dynamics is included in the authoritative financial packet.
Management cautions that results for the quarter are not necessarily indicative of future performance. Capital requirements remain dependent on multiple variables, including the continued marketing and selling of Recorlev, Gvoke, and Keveyis. Liquidity planning must account for these ongoing needs, though no specific near-term funding actions or debt maturity triggers are quantified in the audited financial data.